Dhaka Tribune

Angion Biomedica to rise 1,000% at the open - a purely nominal change, no worries

Angion Biomedica (NASDAQ: ANGN) will be changing to (NASDAQ: ELTX) at the open this morning. This is all a part of the merger with Elicio Therapeutics from January - with an assist from a little stock ...
AOL

Here's Why We're Watching Angion Biomedica's (NASDAQ:ANGN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...
Yahoo Finance

Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...
MedCity News

Angion’s kidney therapy advances

Angion Biomedica announced positive phase II clinical trial results for its drug ANG-3777, which treats acute kidney injuries. The study tested whether the small molecule could help kidney transplant ...
Yahoo Finance

The Last 12 Months Of Insider Transactions At Angion Biomedica

In fact, the recent purchase by President Jay Venkatesan was not their only acquisition of Angion Biomedica shares this year. They previously made an even bigger purchase of US$730k worth of shares at ...
MedCity News

Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger

Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...
Business Insider

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase ...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...
Nasdaq

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not ...
pharmaphorum

Angion stock falls after agreeing Elicio Therapeutics merger

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...
MM&M

Elicio Therapeutics merges with Angion Biomedica to focus on cancer vaccines and immunotherapies

Elicio Therapeutics, a clinical-stage biotech, is merging with Angion Biomedica Corp to form a company that will focus on immunotherapies using Elicio’s proprietary lymph node-targeting Amphiphile ...
Business Wire

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...